All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @duongsonmy6 on TikTok · 20s|Watch on TikTok

Tirzepatide and semaglutide sold via TikTok comments: what's real

duongsonmy6

TikTok creator

1.9K viewsWatch on TikTok

Quick answer

The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims. Both compounds have strong clinical evidence for weight reduction but are FDA-regulated drugs requiring a valid prescription and licensed dispensing. Purchasing either through unverified online sellers carries documented risks including dosing inaccuracies, contamination, and absence of medical oversight.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Tirzepatide and semaglutide sold via TikTok comments: what's real, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Tirzepatide and semaglutide sold via TikTok comments: what's real" from duongsonmy6. We read the clip as a Peptide social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims.

The reason this review is not generic is the source wording and the canonical claim label "peptides type 1 to get price list coa and group link type 1 to get pr." In this clip, the useful excerpt is: "Type "1" to get price list COA and group link!" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide, citing adverse events from dosing errors and contaminated products sourced outside licensed pharmacies.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims. Both compounds have strong clinical evidence for weight reduction but are FDA-regulated drugs requiring a valid prescription and licensed dispensing. Purchasing either through unverified online sellers carries documented risks including dosing inaccuracies, contamination, and absence of medical oversight.
  • Tirzepatide produced up to 22.5% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), but those results came from regulated, dosed pharmaceutical products under clinical supervision.
  • The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide, citing adverse events from dosing errors and contaminated products sourced outside licensed pharmacies.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Tirzepatide produced up to 22.5% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), but those results came from regulated, dosed pharmaceutical products under clinical supervision.
  • The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide, citing adverse events from dosing errors and contaminated products sourced outside licensed pharmacies.
  • Selling tirzepatide or semaglutide without a valid prescription and licensed dispensing is a federal legal violation in the United States, regardless of whether a COA is provided.
  • A certificate of analysis from a third-party lab does not equal FDA-grade manufacturing standards, sterility testing, or accurate unit dosing.
  • The 'type 1 for price list' DM funnel bypasses any prescriber relationship, meaning no one screens buyers for contraindications like personal or family history of medullary thyroid carcinoma or pancreatitis.
  • The video's spoken content contains zero health claims, a deliberate strategy that keeps the creator's words clean while the hashtags and caption do the sales work.
  • Patients interested in GLP-1 or GIP-based therapies should pursue them through a licensed telehealth or in-person provider who can review labs, history, and adjust dosing based on response.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @duongsonmy6 actually say?

Almost nothing medically relevant. The transcript is entirely a birthday celebration: "What a birthday," "I have goosebumps everywhere," "This is out of this world." That is the complete verbal content of the video. There are zero claims about peptides, weight loss, tirzepatide, or semaglutide in the spoken words themselves. The entire medical framing comes from the caption and hashtags, not the creator's mouth.

This is a deliberate content strategy worth naming directly. By keeping the spoken content innocuous, the creator avoids making explicit drug claims while the hashtags do the marketing work. The caption instructs viewers to type "1" to receive a price list and certificate of analysis, which signals this is a sales operation, not an educational account. The "COA" reference implies they are selling compounds they claim have been independently tested.

Does the science back this up?

There is no science to evaluate here because no claims were made. But the product category implied by the hashtags, specifically tirzepatide and semaglutide sold through a DM-based price list, sits in heavily regulated territory with real safety stakes.

Tirzepatide (brand name Mounjaro/Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist. Its efficacy is well-documented. Jastreboff et al. (2022, New England Journal of Medicine) found up to 22.5% body weight reduction in adults with obesity over 72 weeks. Semaglutide data from Wilding et al. (2021, NEJM) showed around 15% weight loss. These are real, significant results from pharmaceutical-grade, regulated products. What cannot be assumed is that any compound sold via TikTok DM carries equivalent purity, dosing accuracy, or safety profile. The FDA has explicitly warned about compounded versions of these drugs, noting contamination and dosing errors as documented risks.

What did they get wrong (or right)?

The creator got nothing medically wrong in speech because they said nothing medical. But the sales architecture around the video raises serious concerns that deserve plain language.

  • Selling tirzepatide or semaglutide outside a licensed pharmacy and without a valid prescription is illegal under federal law in the United States, regardless of whether a COA is provided.
  • A certificate of analysis from an unverified third-party lab does not equal FDA approval or pharmaceutical-grade manufacturing standards.
  • The "type 1 for price list" model is a classic gray-market sales funnel that bypasses the prescriber relationship entirely, meaning no one is screening for contraindications like pancreatitis history, thyroid cancer risk, or drug interactions.

To be fair, the creator never explicitly told anyone to inject anything or skip a doctor. But the funnel they are running makes that outcome structurally likely for buyers who follow through.

What should you actually know?

If you are interested in GLP-1 or GIP-based therapies for weight management, the evidence base is genuinely strong. These are not fringe compounds. But sourcing matters enormously, and this is where the TikTok DM market creates real patient risk.

The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide products, noting reports of adverse events tied to incorrect dosing units, contaminated vials, and products that were not what sellers claimed. The absence of a physician relationship means no one is adjusting your dose if you develop nausea, gastroparesis symptoms, or injection site reactions.

FormBlends operates under licensed medical supervision for a reason. Any peptide or pharmaceutical therapy should involve a clinician who knows your labs, your history, and your goals. A price list sent via DM is not a treatment plan.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

duongsonmy6 · TikTok creator

1.9K views on this video

Type “1” to get price list COA and group link!! Type “1” to get price list COA and group link!! Type “1” to get price list COA and group link!! Type “1” to get price list COA and group link!! #peptide #loseweight #tirzepatide #semaglutide #weightloss

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide produced up to 22.5% body weight reduction in the?

Tirzepatide produced up to 22.5% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), but those results came from regulated, dosed pharmaceutical products under clinical supervision.

What does the video say about the fda?

The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide, citing adverse events from dosing errors and contaminated products sourced outside licensed pharmacies.

What does the video say about selling tirzepatide?

Selling tirzepatide or semaglutide without a valid prescription and licensed dispensing is a federal legal violation in the United States, regardless of whether a COA is provided.

What does the video say about a certificate of analysis from a third-party lab does not?

A certificate of analysis from a third-party lab does not equal FDA-grade manufacturing standards, sterility testing, or accurate unit dosing.

What does the video say about the 'type 1 for price list' dm funnel bypasses any?

The 'type 1 for price list' DM funnel bypasses any prescriber relationship, meaning no one screens buyers for contraindications like personal or family history of medullary thyroid carcinoma or pancreatitis.

What does the video say about the video's spoken content contains zero health claims, a deliberate?

The video's spoken content contains zero health claims, a deliberate strategy that keeps the creator's words clean while the hashtags and caption do the sales work.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by duongsonmy6, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.